<DOC>
	<DOCNO>NCT01718327</DOCNO>
	<brief_summary>For patient non-resectable cholangiocarcinoma , gemcitabine cisplatin consider reference treatment first line chemotherapy . However , outcomes patient remain limited therefore effective drug warrant . The context disease current data sunitinib suggest sunitinib may activity patient advance non resectable cholangiocarcinoma . Thereby , propose conduct open label single arm trial aim evidence activity sunitinib patient population .</brief_summary>
	<brief_title>A Study Sunitinib Patients With Advanced Cholangiocarcinoma</brief_title>
	<detailed_description>The primary objective evaluate overall survival patient advance unresectable cholangiocarcinoma treat continuously sunitinib second line dose 37.5 mg per day , one line chemotherapy determine whether sunitinib deserves study indication . The secondary objective - To evaluate criterion efficacy - To evaluate effect sunitinib tumor angiogenesis - To characterize safety profile sunitinib - To identify marker associate response sunitinib</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Written informed consent give accord ICH/GCP , local regulation . 2 . Histologically cytologically proven intrahepatic cholangiocarcinoma . 3 . Disease amenable surgery , radiation , combine modality therapy curative intent . 4 . Gemcitabine without platinum pretreated patient document progression 5 . Local , locallyadvanced metastatic disease document show progression scan ( CT , MRI ) . 6 . Measurable tumor accord RECIST criterion least one unidimensionally measurable target lesion 7 . No evidence biliary duct obstruction unless obstruction control local treatment , biliary tree decompress endoscopic percutaneous stenting subsequent reduction bilirubin £ 1.5xULN . 8 . Age 18 80 year old 9 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status :01 10 . Life expectancy ≥ 3 month . 11 . Ability swallow oral compound . 12 . No acute toxic effect previous treatment superior grade 1 . 13 . Laboratory requirement : Hematologic : absolute neutrophil count ( ANC ) 1.5 x 103/mm3 , platelet 100 x 103/mm3 , hemoglobin 9 g/dl Hepatic : Bilirubin &lt; 1.5 x upper normal limit ( ULN ) , alkaline phosphatase ( AP ) 5xULN . AST ALT may 5 x ULN Patients jaundice Prothrombin time partial thromboplastin time 1.7 xULN , serum albumin 2.8 g/dl . Renal : Serum creatinine 1.5 xULN , clearance &gt; 60 ml/min . 14 . Normal cardiovascular function 15 . Adequate organ function 16 . No cardiovascular event year prior study entry 17 . Female patient must surgically sterile postmenopausal , must agree use effective contraception period therapy . All female patient reproductive potential must negative pregnancy test ( serum urine ) within 7 day prior start study drug . Male patient must surgically sterile must agree use effective contraception period therapy . The definition effective contraception base judgment investigator designate associate 18 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial 19 . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure 20 . Registration national health care system ( CMU include ) . 1 . Hilar cholangiocarcinomas , cholangiocarcinomas locate gall bladder , hepatic capsule effraction , extrahepatic primary cholangiocarcinoma , carcinoma Water ampullum . 2 . Prior treatment chemotherapy gemcitabine and/or platinum . 3 . Concomitant treatment chemotherapy , chemoembolization therapy , immunotherapy , antitumoral hormonotherapy investigational anticancer agents.. 4 . Prior treatment tyrosine kinase inhibitor antiVEGF angiogenic inhibitor . 5 . Diagnosis second malignancy within last 5 year , except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix uterus . 6 . Treatment potent CYP3A4 inhibitor inducer within 7 12 day , respectively prior study drug administration . 7 . Preexisting thyroid abnormality thyroid function maintain normal range medication . 8 . Concomitant treatment therapeutic dos anticoagulant ( low dose warfarin ( Coumadin ) 2 mg PO daily deep vein thrombosis prophylaxis allow ) . 9 . Unstable systemic disease include uncontrolled hypertension ( &gt; 150/100 mmHg despite optimal medical therapy ) active uncontrolled infection . 10 . Drug proarrhythmic potential ( terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide flecainide ) . 11 . Any follow within 12 month prior study drug administration : myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . 12 . Abnormal cardiac function abnormal 12 lead ECG . Ongoing cardiac dysrhythmias NCI CTC grade2 , atrial fibrillation grade , prolongation QTc interval &gt; 450 msec male &gt; 470 msec female . 13 . Symptomatic brain metastasis , spinal cord compression , new evidence brain leptomeningeal disease . 14 . Current treatment investigational medicinal product . 15 . Positive test human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness 16 . Pregnancy breastfeed . 17 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
</DOC>